Skip to content

Study · Randomized controlled trial · 2001

12 results

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.

The source lists no authors.

Human reproduction (Oxford, England)1 Apr 2001Cited by 185 (Europe PMC)

PMID11278211 (opens in a new tab)DOI10.1093/humrep/16.4.644 (opens in a new tab)PepBankPUB-11278211
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, the ganirelix regimen lasted 9 versus 26 days with triptorelin, a difference of 17 days.

    In plain wordsIn ovarian stimulation, the ganirelix regimen lasted 9 days versus 26 days with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseTreatment duration
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · on average 9 days (ganirelix regimen)As given in this study (human).

    Measurements

    Mean regimen duration
    9 days
    ganirelix
    Mean regimen duration
    26 days
    triptorelin
    Mean difference in regimen duration
    17 days
    ganirelix shorter than triptorelin

    Source sentences

    Summary
    The ganirelix regimen was on average 17 days shorter (9 versus 26 days) compared to the triptorelin regimen.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, median total FSH dose was 1350 IU with ganirelix versus 1800 IU with triptorelin, 450 IU less.

    In plain wordsIn ovarian stimulation, median FSH use was 1350 IU with ganirelix versus 1800 IU with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseTotal recombinant FSH dose
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · on average 9 days (ganirelix regimen)As given in this study (human).

    Measurements

    Median total recombinant FSH dose
    1350 IU
    ganirelix
    Median total recombinant FSH dose
    1800 IU
    triptorelin
    Median difference in FSH dose
    450 IU
    ganirelix lower than triptorelin

    Source sentences

    Summary
    The median total dose of recombinant FSH (Puregon) used was 450 IU less (1350 versus 1800 IU) in the ganirelix protocol.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, initial follicular growth was faster with ganirelix than triptorelin.

    In plain wordsIn ovarian stimulation, initial follicular growth was faster with ganirelix than triptorelin.

    Peptide
    Ganirelix
    Outcome
    IncreaseInitial follicular growth
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · on average 9 days (ganirelix regimen)As given in this study (human).

    Source sentences

    Summary
    The initial follicular growth was faster and, consequently, oestradiol concentrations were higher in the ganirelix group.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, oestradiol concentrations were higher in the ganirelix group than the triptorelin group, alongside faster initial follicular growth.

    In plain wordsIn ovarian stimulation, oestradiol concentrations were higher with ganirelix than triptorelin, alongside faster early follicle growth.

    Peptide
    Ganirelix
    Outcome
    IncreaseOestradiol concentrations
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneous · on average 9 days (ganirelix regimen)As given in this study (human).

    Source sentences

    Summary
    The initial follicular growth was faster and, consequently, oestradiol concentrations were higher in the ganirelix group.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  5. 05HumanRandomized controlled trialEfficacy outcome

    On HCG day, mean follicle counts of at least 11 mm were 10.1 with ganirelix versus 10.7 with triptorelin.

    In plain wordsOn HCG day, mean counts of follicles at least 11 mm were 10.1 with ganirelix versus 10.7 with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseFollicles at least 11 mm on HCG day
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Follicles >=11 mm on HCG day, mean
    10.1 follicles
    ganirelix group
    Follicles >=11 mm on HCG day, mean
    10.7 follicles
    triptorelin group

    Source sentences

    Summary
    On the day of human chorionic gonadotrophin (HCG), the mean number of follicles > or = 11 mm was 10.1 and 10.7 and the median serum oestradiol concentration was 1090 and 1370 pg/ml in the ganirelix and triptorelin groups respectively.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  6. 06HumanRandomized controlled trialEfficacy outcome

    On HCG day, median serum oestradiol was 1090 pg/ml with ganirelix versus 1370 pg/ml with triptorelin.

    In plain wordsOn HCG day, median oestradiol was 1090 pg/ml with ganirelix versus 1370 pg/ml with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseOestradiol on HCG day
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Serum oestradiol on HCG day, median
    1090 pg/ml
    ganirelix group
    Serum oestradiol on HCG day, median
    1370 pg/ml
    triptorelin group

    Source sentences

    Summary
    On the day of human chorionic gonadotrophin (HCG), the mean number of follicles > or = 11 mm was 10.1 and 10.7 and the median serum oestradiol concentration was 1090 and 1370 pg/ml in the ganirelix and triptorelin groups respectively.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, mean oocytes retrieved per attempt were 7.9 with ganirelix versus 9.6 with triptorelin.

    In plain wordsIn ovarian stimulation, mean oocytes retrieved were 7.9 with ganirelix versus 9.6 with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseOocytes retrieved
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Oocytes retrieved per attempt, mean
    7.9 oocytes
    ganirelix group
    Oocytes retrieved per attempt, mean
    9.6 oocytes
    triptorelin group

    Source sentences

    Summary
    Per attempt, 7.9 and 9.6 oocytes (mean) were retrieved in the ganirelix and triptorelin groups respectively.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, fertilization rates were comparable at 64.0% with ganirelix and 64.9% with triptorelin.

    In plain wordsIn ovarian stimulation, fertilization rates were comparable with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedFertilization rate
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Fertilization rate
    64%
    ganirelix group
    Fertilization rate
    64.9%
    triptorelin group

    Source sentences

    Summary
    The fertilization rates (64.0% ganirelix and 64.9% triptorelin) and the mean number of good quality embryos (2.7 and 2.9) were comparable in both treatment groups.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, mean good quality embryo counts were comparable at 2.7 with ganirelix and 2.9 with triptorelin.

    In plain wordsIn ovarian stimulation, good quality embryo counts were comparable with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedGood quality embryos
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Good quality embryos, mean
    2.7 embryos
    ganirelix group
    Good quality embryos, mean
    2.9 embryos
    triptorelin group

    Source sentences

    Summary
    The fertilization rates (64.0% ganirelix and 64.9% triptorelin) and the mean number of good quality embryos (2.7 and 2.9) were comparable in both treatment groups.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, implantation rates were identical at 22.9% with ganirelix and triptorelin.

    In plain wordsIn ovarian stimulation, implantation rates were identical with ganirelix and triptorelin.

    Peptide
    Ganirelix
    Outcome
    No significant changeImplantation rate
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Implantation rate
    22.9%
    ganirelix and triptorelin groups (identical)

    Source sentences

    Summary
    The implantation rate was identical (22.9%).
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  11. 11HumanRandomized controlled trialEfficacy outcome

    In ovarian stimulation, ongoing pregnancy rates per attempt were 31.0% with ganirelix versus 33.9% with triptorelin.

    In plain wordsIn ovarian stimulation, ongoing pregnancy rates were 31.0% with ganirelix versus 33.9% with triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseOngoing pregnancy rate
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Ongoing pregnancy rate per attempt
    31%
    ganirelix group
    Ongoing pregnancy rate per attempt
    33.9%
    triptorelin group

    Source sentences

    Summary
    The ongoing pregnancy rate per attempt was 31.0 and 33.9% in the ganirelix and triptorelin groups respectively.
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).
  12. 12HumanRandomized controlled trialSafety outcome

    In ovarian stimulation, local skin reactions occurred in 11.9% with ganirelix versus 24.1% with triptorelin, a 2-fold lower proportion.

    In plain wordsIn ovarian stimulation, local skin reactions were less frequent with ganirelix than triptorelin.

    Peptide
    Ganirelix
    Outcome
    DecreaseLocal skin reactions
    Study

    n: not reported in source

    Comparator
    Triptorelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.25 mg · subcutaneousAs given in this study (human).

    Measurements

    Subjects with at least one local skin reaction
    11.9%
    ganirelix group
    Subjects with at least one local skin reaction
    24.1%
    triptorelin group

    Source sentences

    Summary
    The ganirelix regimen showed an improved local tolerance in that the percentage of subjects with at least one local skin reaction was 2-fold lower than in the triptorelin group (11.9 versus 24.1%).
    2 context sentences
    Summary · context
    This multicentre, randomized study was performed to assess the efficacy and safety of 0.25 mg ganirelix (Orgalutran, Antagon) treatment, using triptorelin (Decapeptyl) in a long protocol as a reference treatment.
    Summary · context
    In total, 236 subjects were randomized to treatment with ganirelix (0.25 mg, s.c.) and 119 to triptorelin (0.1 mg, s.c.) treatment (treatment ratio 2:1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.